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Abstract Atherosclerosis (AS) is a chronic, progressive,
multifactorial disease mostly affecting large and medium-
sized elastic and muscular arteries. It has formerly been
considered a bland lipid storage disease. Currently, multiple
independent pathways of evidence suggest this pathological
condition is a peculiar form of inflammation, triggered by
cholesterol-rich lipoproteins and influenced both by envi-
ronmental and genetic factors. The Human Genome Project
opened up the opportunity to dissect complex human traits
and to understand basic pathways of multifactorial diseases
such as AS. Population-based association studies have
emerged as powerful tools for examining genes with a role
in common multifactorial diseases that have a strong envi-
ronmental component. These association studies often esti-
mate the risk of developing a certain disease in carriers and
non-carriers of a particular genetic polymorphism.
Dissecting out the influence of pro-inflammatory genes
within the complex pathophysiology of AS and its compli-
cations will help to provide a more complete risk assessment
and complement known classical cardiovascular risk fac-
tors. The detection of a risk profile will potentially allow
both the early identification of individuals susceptible to
disease and the possible discovery of potential targets for
drug or lifestyle modification; i.e. it will open the door to
personalized medicine.
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Introduction
Inflammation is a well-conserved process, evolved to enhance
the organism’s resistance to infections, and to lead to tissue
repair after various forms of injury. It is considered as a
complex and potentially life-threatening condition, orchestrat-
ed by a variety of chemical mediators, signaling pathways,
and cell types. Its initiation and perpetuation are the result of
several characteristic functional and structural changes of the
microcirculation, ranging from the vasomotor dysfunction
(impaired vessel dilation and constriction), adhesion and
transendothelial migration of leukocytes, to endothelial barrier
dysfunction (increased vascular permeability), and blood ves-
sel proliferation (angiogenesis). Changes in physiological he-
mostasis also accompany inflammation as consequence of the
action of pro-inflammatory cytokines, chemokines, adhesion
molecules, tissue factor expression, platelet and endothelial
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activation. Its evocation may be caused by chronic inflamma-
tion associated-endothelial damage, leading to the loss of
physiologic anticoagulant, antiaggregant and vasodilatory
properties of endothelium. On the other hand, coagulation
also augments inflammation, causing a vicious cycle. This is
mainly achieved by means of thrombin-induced secretion of
pro-inflammatory cytokines and growth factors [1].
When chronic inflammation moves beyond local tissues
and into the lining of blood vessels and organs, systemic
inflammation occurs. Chronic systemic inflammation is
the result of release of pro-inflammatory cytokines from
immune-related cells and the chronic activation of the innate
immune system. In atherosclerosis (AS), inflammation in
the vascular wall and the release of inflammatory cytokines
from macrophages is considered the main mechanism. How-
ever, infection (i.e. Chlamydia or Helicobacter pylori infec-
tion and periodontal disease) is considered as an underlying
cause of systemic inflammation [2]. It can contribute to the
development or progression of certain conditions. A char-
acteristic biomarker of systemic inflammation is C-reactive
protein (CRP), an acute phase protein, whose levels increase
only during an inflammatory process in the body [3••].
Inflammation in Atherosclerosis as the Prevalent Process
AS is a chronic progressive disorder, principally affecting
large and medium-sized elastic and muscular arteries. It has
formerly been considered a bland lipid storage disease.
Currently, multiple independent pathways of evidence sug-
gest this pathological condition as a peculiar form of inflam-
mation, triggered by cholesterol-rich lipoproteins and other
noxious factors, such as cigarette smoke, diabetes mellitus
and hypertension. Inflammation seems, indeed, to be the
prevalent process of AS, evocated by multiple risk factors
and responsible for the altered arterial biology associated
with AS complications [3••].
The initial stimulus inducing the inflammatory process
has not been fully identified. However, endothelial dys-
function plays a crucial role in inflammation evocation.
Several causes are associated with endothelial dysfunction,
including the major number of traditional AS risk factors,
i.e. elevated low density lipoprotein (LDL) values, free
radicals caused by cigarettes smoking, hypertension, dia-
betes, elevated levels of homocysteine, but also infections
caused by Chlamydia pneumoniae, Herpes simplex virus,
Cytomegalovirus and Helicobacter pylori [4]. Thus, AS
may be considered as a characteristic response both to
endothelium injury and to the consequent endothelial dys-
function. Endothelial dysfunction leads to compensatory
responses modifying the normal homeostatic properties of
the endothelium [5] and favouring the expression of adhe-
sion molecules, which bind to various classes of leuko-
cytes [6, 7].
Both innate and clonotypic immune cells are involved in
this clinical inflammatory disorder. Monocytes are the
prominent cellular component of innate immune response
during atherogenesis. They, recruited through activated en-
dothelium, differentiate into macrophages. This step is
critical for the onset of AS, and is associated with up-
expression and regulation of pattern-recognition receptors,
including scavenger receptors (able to internalize a broad
range of molecules) and Toll-like receptors (TLRs) (whose
activation can initiate a signal cascade leading to cell acti-
vation) [8, 9]. The activated macrophages produce inflam-
matory cytokines, proteases, cytotoxic oxygen and nitrogen
radical molecules.
Accumulating evidence also supports the involvement of
clonotypic immune cells in AS and its complications. In
particular, a T cell infiltration is always present in AS
lesions. Several CD4+ T cell subsets have been observed.
A type-1 helper T (Th1) response seems to be involved in
the activation of macrophages and the consequent evocation
of an inflammatory response similar to delayed hypersensi-
tivity and with the typical functions of response against
intracellular pathogens. The AS lesions contain cytokines
promoting a Th1 response. Activated Th1 cells differentiate
into Th1 effector cells and produce the macrophage-
activating cytokine interferon(IFN)-γ, which augments the
synthesis of the inflammatory cytokines, such as Tumor
Necrosis Factor(TNF)-α and Interleukin (IL)-1. These cyto-
kines stimulate the production of numerous inflammatory
and cytotoxic molecules in macrophages and vascular cells.
Thus, Th1 response appears to exacerbate AS [8]. Another T
cell subtype, regulatory T cell (Treg), seems to play a mod-
ulatory role in AS, controlling inflammatory responses
through the secretion of anti-inflammatory cytokines, such
as IL-10 and transforming growth factor-β [10]. Thus, the
development of AS could be the effect of the imbalance
among different T cells populations.
Several data from human and animals studies confirm the
key role of inflammation in the atherogenesis: significant
elevation of plasma levels of inflammatory biomarkers pre-
dicts outcomes in patients with acute coronary syndromes,
independently on myocardial damage. In particular, levels
of CRP or IL-6 have been suggested to be significant pre-
dictive risk factors for future cardiovascular events [8, 11].
In addition, some treatments able to reduce the risk of
cardiovascular events seem to limit inflammation: this is
the case of statins, whose anti-inflammatory effects are not
only related with the lipid-lowering effect [12, 13].
Furthermore, several clinical conditions characterized by
a chronic systemic inflammatory state have recently been
associated with an increased cardiovascular risk, not
explained by traditional risk factors. Many epidemiologic
observations have linked some diseases with inflammatory
systemic pathophysiology with cardiovascular events, such
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as autoimmune diseases as rheumatoid arthritis (RA) or
systemic lupus erythematosus (SLE). In fact, an increasing
body of evidence supports the hypothesis that atherosclero-
sis and autoimmune diseases share many similarities, such
as the presence of an inflammatory infiltrate in the unstable
coronary lesion that is indistinguishable respect to inflam-
matory synovitis seen in RA [14]. Moreover, an increased
mortality has been demonstrated, largely due to cardiovas-
cular diseases (CVD), in subjects affected by RA or SLE
[15–17]. Interestingly, the treatment with methotrexate, able
to reduce immune-inflammatory burden in these diseases,
seems to limit cardiovascular risk in patients with chronic
inflammatory diseases [18, 19].
Several other clinical conditions characterized by a
chronic inflammatory state have been found to be associated
with increased risk of AS and CVD. For example, coronary
heart disease (CHD) occurs much more frequently in pa-
tients with end-stage renal disease (ESRD) than in the
general population, accounting for 45–50 % of deaths in
patients receiving dialysis [20]. It has been hypothesized
that chronic inflammation characterizing ESRD may accel-
erate the development and progression of AS.
Other clinical conditions, associated with a low grade
chronic inflammation often due to chronic infection, have
been associated with an increased risk of CVD, even if in
lesser measure. An example is periodontal disease, which is
actually considered a possible cause of cardiovascular dis-
ease [21, 22•]. Thus, the concept of inflammation as a
cardiovascular risk factor has spread in the scientific com-
munity [23].
AS arises as a multistep clinical condition, characterised
by a series of events whose individual probability and
timing vary with risk factors and intrinsic ability of self-
repair for the artery. Its progression is generally assumed as
irreversible and one-directional as a function of time. How-
ever, for each step, a small reverse probability exists [24]. It
has been, indeed, evidenced that some individuals with a
genetically substantial ability for self-repair of their arteries,
even in the presence of potent risk factors, remain sheltered
from the consequences of AS and related thromboembolic
events [24].
Genetic Polymorphisms which Modulate Inflammation,
AS Onset and Progression, and CVD Complications
A study performed 25 years ago for identifying genetic and
environmental influences of premature death in adult
adoptees concluded that premature death in adults has a
strong genetic background, especially death due to infec-
tions and vascular causes [25]. Therefore, the inflammatory
process, involved both in response to infection and in AS,
has a strong heritable component. Thus, the analysis of the
genes that are key nodes of the inflammatory response
might in part clarify by the pathophysiology of AS and its
complications.
The Human Genome Project opened up the opportunity
to dissect complex human traits and to understand basic
pathways of health and disease. Population-based associa-
tion studies have emerged as powerful tools for examining
genes with a role in common multifactorial diseases that
have a strong environmental component. These association
studies often estimate the risk of developing a certain dis-
ease in carriers and non-carriers of a particular genetic
polymorphism. The majority of the genetic variants studied
are common single nucleotide polymorphisms (SNPs) that
occur with a frequency of>1 % in the normal population. It
is estimated that approximately 3.5 million SNPs are present
in the human individual genome [26, 27]. Most of these
SNPs do not occur in the coding sequences. However,
although they are not associated with alteration in the amino
acid sequence, they may have functional consequence, if,
for example, they are localized in the promoter region.
There has been an exponential increase in the number of
published genetic association studies. Quite often, a report
of a single genetic marker is published with great promise;
however, it is followed by several negative studies that fail
to reproduce the original observation. There is no doubt that
the strategy of genetic association studies could be a pow-
erful tool for dissecting human diseases, provided that cer-
tain principles are observed to minimize the chances of false
positive and negative reports [28].
In the following sections, we discuss the role of SNPs
that modulate inflammation and AS and CVD risk. Three
genetic approaches: candidate gene approach, meta-analysis
and genome-wide association studies have been used to
assess SNPs and AS and CVD, including CHD and Myo-
cardial Infarction (MI) risk.
Candidate Gene Approach and Meta-Analysis
The candidate gene approach is a hypothesis-driven method
widely employed by case–control studies. In these studies,
the genotype and allele frequencies of two populations are
compared: one affected and one unaffected by a complex
disease. If the identified allelic variants are more prevalent
in the affected population as compared to unaffected, these
genotypes are associated with the disease. The number of
reported studies on the association between one or multiple
SNPs in inflammation-related pathways and CVD risk is
greatly increasing, event though a large number of these
studies show inconsistent results (for an extensive analysis
of “old” data, refer to [29]). Consistent replication in differ-
ent populations has been argued as strong evidence of a true
association. However, the genetics of AS is both complex
and intriguing and may alter according to sex and age group.
The lack of replication may not necessarily imply a false
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association, but might simply point to the need for more
studies in certain populations or more detailed study of the
function of a particular gene, taking into account different
gene environment interactions. It is already accepted that the
cardiovascular/ atherosclerosis-related phenotype is strongly
affected by life-style and environmental factors and by
complex epistatic and pleiotropic effects in several genes.
So, small contribution of a single novel polymorphism to
the overall risk of multifactorial diseases, such as CVD and
MI, might be obscured by the presence of one or more
dominant classical risk factors [29].
However, some interesting data have recently been
obtained, such as those derived by meta-analysis. Meta-
analysis provides a mean to quantitatively synthesize asso-
ciation data across studies of the same genetic variant. Thus,
the use of meta-analyses has recently become an important
part of genetic research mainly to reconcile previously
conducted studies that gave inconsistent results [30].
A recent meta-analysis assessed the association between
Asp299Gly (+896A>G; rs4986790) polymorphism in TLR-
4 gene and AS risk. This missense polymorphism alters the
extracellular domain of TLR-4, so it attenuates the TLR-4
signaling pathway and diminishes the inflammatory re-
sponse to Gram-negative pathogens. In particular, it may
influence inflammatory responses and the risk of major
inflammatory age-related diseases by affecting the produc-
tion of inflammatory mediators. To clarify and confirm the
biological effects of +896A>G SNP and its role in the
pathophysiology of age-related diseases and longevity, we
recently assessed the levels of IL-6, TNF-α, IL-10 and
eicosanoids after in vitro stimulation with lipopolysaccaride
(LPS) of whole blood samples from 50 young healthy
Sicilians, screened for the presence of this SNP. Both pro-
inflammatory cytokines and eicosanoids were significantly
lower in carriers bearing the TLR-4 polymorphism, whereas
the anti-inflammatory IL-10 values were higher. So, the
TLR-4 receptor, activated by pathogens or endogenous mol-
ecules, would have the role of hub in the inflammatory
responses involved in the pathophysiology of AS [31, 32].
A total of 15 case–control studies with 9,989 cases and
6,746 controls were included in the meta-analysis, and no
statistically significant association was found between the A
allele and the AG/GG genotype and the risk of AS by
random effects model [33]. On the other hand, other studies
have reported an association in specific subgroups [34]
(Table 1). Further studies estimating the effect of gene-
gene and gene-environment interactions may eventually
provide a better comprehensive understanding, although
the relatively low prevalence of the 896G allele is a potential
limitation in association studies [34].
Other inflammatory molecules seem to have a crucial role
in AS. Among these, monocyte differentiation antigen CD14
is considered an important cell-activating mediator of
inflammatory responses that may result in AS, CHD, throm-
bus formation, and MI. A common -260C>T polymorphism
in the promoter of the CD14 gene, the trans-membrane recep-
tor of LPS, has been inconsistently associated with CHD. This
C>T SNP, in position −260 (rs259190) of the promoter, has
been shown to increase transcriptional activity associated with
enhanced expression of CD14 on monocytes [35]. A recent
meta-analysis of 28 studies involving a total of 13,335 CHD
cases and 7,979 controls for -260C>T of the CD14 gene
evaluated the effect of CD14 on genetic susceptibility for
CHD. An overall random effect of 1.24 odds ratio (ORs)
was found for the T allele. Significant results were also ob-
served using dominant or recessive genetic model. After strat-
ification by ethnicity, significant results were found in East
Asians, but not in Caucasians and other ethnic populations in
all genetic models. Thus, the results of this meta-analysis
suggest that the CD14 -260C>T polymorphism is a risk factor
of CHD, especially in East Asians [36].
Other relevant data analyzed the association of genetic
variants in genes coding for cytokines, adhesion molecules
and chemokines. Concerning adhesion molecules, the
ICAM-1 gene -469E>K polymorphism, known to influence
molecule serum levels [37], has been reported to be associ-
ated with CHD, but results are conflicting. A systematic
review and meta-analysis of the published studies were
performed to gain a clearer understanding of this association.
The pooled result showed that the ICAM-1 gene -469E>K
polymorphism was significantly associated with an increased
risk of CHD. Subgroup analysis supported the results in Asian
and Caucasian populations [38].
Several studies have also reported apparently conflicting
findings about the effects of TNF-α and IL-6 SNPs, such as
TNF-α -308G>A and IL-6 -174G>C promoter SNPs on
CHD susceptibility. A systematic review and meta-analysis
recently investigated the association between the TNF-α -
308G>A gene variant, responsible for an increased cytokine
production [39], and CHD predisposition in 24 studies pro-
viding data for 9,921 cases and 7,944 controls. Pooled
analysis based on ORs adjusted by CHD risk factors showed
that carrying the TNF-α gene A variant conferred a 1.5-fold
increased risk of developing CHD in Caucasian population
[40]
Another recent meta-analysis evaluated the IL-6 -174 G>
C promoter SNP, responsible for different production of this
cytokine [30], in relation to CHD risk, including 6,434
participants of the Rotterdam Study. Analyses on the rela-
tion between genotypes and CHD were performed using
Cox proportional hazards tests, and the association between
genotype and plasma levels of IL-6 and CRP was investi-
gated. All of the analyses were adjusted for age, sex, and
common cardiovascular risk factors. A meta-analysis was
performed, using a random effects model. No association
between genotype and the risk of CHD was observed. The
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polymorphism was not associated with IL-6 levels, but the
C-allele was associated with higher CRP levels. Thus, this
meta-analysis did not show a significant association be-
tween the genotype and the risk of CHD [41].
Monocyte chemoattractant protein-1 (MCP-1) and its re-
ceptor C-C chemokine receptor (CCR) type 2 have also been
implicated in promoting AS. Several studies have investigated
the association between variants of the MCP-1 gene or CCR2
gene and risk of CVD, but results are inconsistent. A meta-
analysis of 20 publications, including 24 studies on two ge-
netic variants—2518A>G in the MCP-1 and 64 V>I in the
CCR2—with a total of 9,844 patients with CVD and 11,821
controls, has recently been performed. The results suggest that
MCP -2518A>G SNP, known to increase MCP-1 production
[42] shows association with an increased risk of CVD in
Caucasians, likely due to publication bias and insufficient
sample size. The CCR2 64 V>I, affecting stability of the
CCR2A isoform [43], has not been found to be associated
with CVD [44].
An alternative approach to studing potential susceptibil-
ity genes for cardiovascular diseases has been followed by
our group, using centenarians as healthy controls. On the
other hand, the major feature characterizing centenarian
offspring is the significant reduction of CVD prevalence.
Thus, alleles associated to CVD susceptibility would not be
included in the genetic background favoring longevity [45].
This kind of approach has been named “positive biology”.
Rather than making diseases the central focus of research,
positive biology seeks to understand the causes of positive
phenotypes, trying to explain the biological mechanisms of
health and wellbeing [46]. In these studies, performed in a
very homogeneous sample of young Sicilian patients and
age-matched controls, we have investigated the eventual
association of some functional SNPs of pro-inflammatory
genotypes with MI. The results described in Table 1 clearly
show that the pro-inflammatory SNPs of TLR-4, CCR5,
cyclo-oxygenase(COX)-2, 5-lypo-oxygenase(LO), lipo-
oxygenase-activating protein(FLAP), Connexin 37 (CX37),
Table 1 Data from our investigations in a Sicilian population
Genes Alleles of SNPs or genetic variants Centenarians Young controls (< 55 years) MI patients(< 55 years) Pp -value
TLR-4 [47] +896A>G1(Asp299Gly; rs4986790) NN=55 males N=127 males N=105 males < 0.001
CCR5 [48] WT>Δ322(rs333) N=123 males N=136 males N=133 males =0.00006
Cox-2 [49] −765G>C3(rs20417) N=96 males N=170 males N=140 males =0.000007
5-LO[49] −1078G>A4(rs2115819)21C>T N=96 males N=170 males N=140 males =0.00003
N=96 males N=170 males N=140 males =0.001
FLAP [49] −336G>A5 N=96 male N=170 males N=140 males =0.0007
Cx37 [50] −1019C>T6 N=56 males N=196 males N=97 males =0.0035
IL-10 [52] −1082G>A7(rs1800896) N=52 males N=110 males N=90 males =0.0003
α1AT [53] 342G>L 8 N=143 N=255 N=127 =0.0000001
MEFV [54] 694 M>V9 N=68 N=196 N=121 =0.003
1 This missense polymorphism alters the extracellular domain of TLR-4, so it attenuates the TLR4 signaling pathway and diminishes the
inflammatory response to Gram-negative pathogens. In particular, it may influence inflammatory responses and the risk of major inflammatory
age-related diseases , such as AS, by affecting the production of inflammatory mediators (see text)
2 A non functional allele, resulting from a 32-bp deletion in exon 4, determines a loss of expression of functional CCR5 receptor. So, this genetic
variant may have a protective role against AMI as consequence of an attenuated inflammatory response that should determine a slower progression
of atherosclerotic lesion among CCR5Δ32 carriers (ref. in 48)
3 Located within a putative binding site for the transcription factor Sp1, associated with a different transcription of gene (ref. in 49)
4 SNPs in promoter region and exon-1 of 5-LO gene, respectively, able to modify the gene transcription or the putative protein (ref. in 49)
5 It has been claimed to be functional, modifying gene transcription or modifying the putative protein derived from gene translation (ref. in 49)
6 This SNP causes a shift from proline to serine at amino acid 319. In a mouse model of atherosclerosis, the mouse Cx37 protein was shown to be
atheroprotective by properly regulating leukocyte recruitment, namely one of the first inflammatory steps in atherosclerotic process (Ref. in 50, 51)
7 SNP in the IL-10 proximal gene region (considered potential target for transcription regulating factors) involved in genetic control of IL-10
production, even if contrasting literature data have been reported. In particular, the homozygous -1082GG genotype seems to be associated with
higher IL-10 production respect to G>A heterozygous and AA homozygous genotypes. Furthermore, this SNP seems to be functionally relevant. It
has been demonstrated that −1082 A carriers (low producers) seem likely develop a major number of chronic inflammatory diseases (ref. in 39, 52)
8 It results in a severe protein deficiency that is characterised in the homozygote state by levels of plasma concentrations that are lower by 84 %
when compared with levels in MM individuals and in the MZ heterozygote state, by intermediate levels that are lower by 17 %. It has been
suggested that α1AT deficiency could lead to less cleaved fragments of α1AT (i.e. the pro-inflammatory peptide C-36) of α1AT in atherosclerotic
plaques, and thereby reduce AS inflammatory process (ref. in 53)
9 This mutation in the pyrin gene is liable to lead to leukocyte survival otherwise designed to follow the apoptotic pathway, increasing the
inflammatory response (ref. in 54)
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IL-10, α1anti-trypsin(AT) and pyrin (MEFV) are overrepre-
sented in patients when compared to centenarians. Recipro-
cally, centenarians possess genetic factors that modulate
ageing processes and are protective for CVD [47–54].
Genome-Wide Association Study
Genome wide association study (GWAS) consists in a scan-
ning of whole genome analyzing markers to find variants
associated with the trait of interest using a case–control study
[55•]. It is important to note that the finding of common
genetic variants with low allelic frequency across studies is
consistently difficult because of the multitude of data to ana-
lyze. Population admixture may produce possible false posi-
tives due to different genetic backgrounds among ethnic
groups is another problem. A family-based association study
and the analysis of geographically isolated population could
permit to improve the detection of true positive genetic asso-
ciation loci, in particular those of modest size.
GWAS is a useful tool for the identification of AS associ-
ated alleles with frequency above 5 % [55•]. Each, taken
singularly, has a moderate or null effect, but borrowing a
concept from pharmacology, it is possible to speculate that
more alleles have, en bloc, a synergic rather than an additional
effect. It means a potentiated effect respect to the sum of
alleles.
With GWAS approach of CVD patients, several loci have
reached a genome wide significant level not always con-
firmed in different studies (Table 2) [57–73]. The locus
9p21 (in particular carrying cyclin-dependent kinase inhib-
itor 2A (CDKN2A), cyclin-dependent kinase inhibitor 2B
(CDKN2B) and ANRIL was identified as the strongest
genetic susceptibility locus for CHD and MI. This was
consistently associated in different studies and in meta-
analysis, and this datum was replicated among different
ethnic groups [59, 60, 62, 65–67].
Concerning inflammatory genes, C-X-C motif ligand 12
(CXCL12), SH2B adaptor protein 3 (SH2B3), a novel Human
Table 2 CHD and MI
sSusceptibility (GWAS) (genes
related to inflammation are in
bold/italics)
BAND GENE REGION(S) REFERENCE
1p13.3 PSCR1, CELSR2, SORT1, MYBPHL [59–62]
1p32.2 PPAP2B [70]
1p32.3 PCSK9 [62]
1q41 MIA 3 [59–62]
2q33 WDR12, ALSC2R13 [62]
2q36 IRS1 [71]
3q22.3 MRAS [63]
6p21.3 HLA [58]
6p21.31 ANKS1A [70]
6q23.2 TCF21 [70]
6p24 PHACTR1 [62]
6q26-27 SLC22A3, LPAL2, LPA [64, 72]
7q32 KLF14 [71]
7q32.2 ZC3HC1 [70]
8p22 NAT2 [71]
9p21 CDKN2A, CDKN2B, ANRIL, MTAP [59, 60, 62, 65–67]
9q34.2 AB0 [59, 70, 73]
10q11. CXCL12>SDF-1 [59, 60, 69]
10q24.32 CYP17A1, CNNM2, NT5C2 [70]
11q23.3 ZNF259, APOA5, A4, C3, A1 [70]
12q24 SH2B3 [57, 68]
12q24.3 HNF1A, C12orf43 [63]
13q34 COL4A1, COL4A2 [70]
14q32.2 HHIPL1 [70]
15q25.1 ADAMTS7 [70, 73]
17p11.2 RASD1, SMCR3, PEMT [70]
17p13.3 SMG6, SRR [70]
17q21.32 UBE2Z, GIP, ATP5G1, SNF8 [70]
19p13.2 LDLR [62, 63]
21q22 SLC5A3, MRPS6, KCNE2 [62]
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Leukocyte Antigen (HLA) locus and the AB0 locus were
identified as significantly associated to CHD.
CXCL12 is a gene encoding for a chemokine involved in
vascular repair and remodeling. It is expressed in athero-
sclerotic lesion, and its effects on platelets could promote
atherothrombosis [56]. It was demonstrated that SNPs
rs1746048 and rs501120, in a region 80 kb downstream of
the CXCL12 gene (on chr 10q11), are associated with
higher CXCL12 plasma levels and higher CXCL12 mRNAs
[60, 69, 71].
SH2B3 encodes for an adaptor protein and promotes a
pro-inflammatory state in human vascular endothelial cells,
where it is expressed. Its SNP rs3184504, whose biological
significance is unknown, determines a missense mutation
and it has been identified as possible driver in coronary
arteries plaque formation and in MI in different populations,
including Europeans [57].
Human Major Histocompatibility Complex (HLA) plays
an important role in inflammation and T cell responses,
closely related to CHD and in particular to the progression
of AS. An association between a novel locus HLA, 6p21.3,
and CHD was found in a well-selected European popula-
tion. In particular, the SNP rs3869109 located in an intra-
genic region between HLA-C and HCG27 (HLA complex
group 27), although the biological basis of this association is
not clear, has reached a genome-wide significance level
[58].
A recent GWAS conducted on level of inflammatory
markers in a Sardinian population highlighted the associa-
tion between CVD and AB0 locus. The association was
established between this locus and IL-6. Subjects homozy-
gous for G allele in rs657152 SNP, corresponding to blood
type 0 carriers, showed higher IL-6 circulating levels respect
to non-0 carriers, although the reason in unknown,
reinforcing a relevant involvement of blood group antigens
in inflammatory process [74]. Indeed, a previous GWAS
demonstrated that a variant in ABO genes can explain the
variation in soluble E-selectin levels [75]. On the whole,
these GWAS might clarify the relation between ABO and
CVD observed in GWAS [59, 70, 73] and in classic case
control studies [73].
Conclusions
In this paper, we reviewed data in the literature, comparing the
gene frequencies between patients and controls of pro-
inflammatory gene polymorphisms potentially related to AS
and its complications. Inflammation represents a key process
involved in the development of the diseases. A large number
of epidemiologic studies have identified significant associa-
tions between the levels of circulating inflammatory bio-
markers and AS and its complications. However, circulating
inflammatory biomarker levels fluctuate in response to acute
infection or tissue damage, which may result in measurement
error because of high intra-individual variation.
In contrast, the study of genetic variants associated with
inflammatory molecules may offer a more accurate picture
of inflammatory status. On the other hand, they might be
unaffected by common, environmental confounding factors.
The characterization of genetic determinants may also pro-
vide further insight into the biological mechanisms regulat-
ing inflammation and their role in pathophysiology of AS.
In the last years, the number of genetic studies demonstrat-
ing associations between different pro-inflammatory gene
polymorphisms and AS and CVD has particularly increased.
However, divergent results exist across population groups,
different sample size studies, and between the types and
severity of CVD and age of subjects.
As a consequence, as discussed, the use of meta-analyses
has recently become an important part of genetic research,
mainly to reconcile previously conducted studies having in-
consistent results.
Today, with the coming of non-biased techniques (i.e.
GWA studies) and the sophisticate genetic analyses, which
enable assessment of multiple genetic variants, a large number
of novel genetic associations of genes coding for the inflam-
matory molecules with AS and its complications have been
identified. In addition, they have provided the basis for sub-
sequent research to assess the causality of these relationships.
However, the high throughput genetic analyses that allow
the simultaneous risk assessment of multiple genetic variants
with sophisticated biostatistical programs are going to allow
for the identification of “genetic signatures” for CVD.
Dissecting out the influence of pro-inflammatory genes within
the complex pathophysiology of AS and CVD will help to
provide a more complete risk assessment and complement
known classical cardiovascular risk factors. The detection of
a risk profile will potentially allow both the early identification
of individuals susceptible to disease and the possible discov-
ery of potential targets for drug or lifestyle modification, i.e. it
will open the door to personalized medicine.
However, a note of caution should be added, that since
the polymorphisms involved are fairly common in the gen-
eral population, there is a strong likelihood that any given
individual will inherit one or more of the high-risk alleles:
the occurrence of the disease is likely to depend on interac-
tion between different high-risk alleles, exposure to patho-
gens, environmental factors, and lifestyle choices.
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